Obesity in the cardiovascular continuum.

Abstract A higher prevalence of coronary heart disease, cardiac and overall mortality is associated with obesity. The development of obesity appear different adaptations in the morphology of cardiac structure and function. Obesity causes eccentric hypertrophy and changes in diastolic function of left ventricle. A systolic on diastolic heart dysfunction results from breakdown compensatory pace to raised wall stress and dilatation of chambers. Obesity does not possess primary cause effect relationship with cardiovascular disease, such as LDL cholesterol. It is regarded by means of facilitating factor such as hypertension, diabetes or cigarette smoking. Adipose tissue in this manner works as the hormone generating tissue, secreting various peptides and secondary messengers and inflammatory cytokines. Pharmacotherapy can be a useful component in the global fight against obesity. Besides repeating re-evaluations of weight loosing drug treatment with respect to efficiency or safety for continuous use, one must not underappreciate the pretreatment risk-assessments and expected benefits of treatment, along with impact on the patient's quality of life and motivation. Pharmacotherapy of obesity is reserved for obese with body mass index (BMI) ≥ 30 kg/m2, but also in individuals with BMI 27,0 and 29,9 kg/m2 and obesity related comorbidities as obstructive sleep apnea, hypertension, dyslipidemias, diabetes and metabolic syndrome. Connections between obesity and cardiovascular diseases (CVD) are acknowledged for over dozen of years, is still a lack of scientific research into the field and a challenge for future studies.